The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer who have failed prior chemotherapy.
“If approved, satraplatin will be the only drug for hormone refractory prostate cancer patients in the second-line setting, and we believe that the convenience of oral dosing and favorable tolerability will also offer an improvement in quality of life,” said Luigi Lenaz, chief scientific officer of Spectrum Pharmaceuticals.
The study showed that pain response rates for patients treated with satraplatin were statistically significantly superior compared to the pain response rates for those patients in the comparator arm. Pain response rates were 24.2% for the satraplatin plus prednisone arm compared with 13.8% for the prednisone arm (p